Autoimmune blistering diseases: promising agents in clinical trials

References

• Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394:882–894.
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017;3(1):17026. doi: 10.1038/nrdp.2017.26
   PubMed Web of Science ®Google Scholar
• Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320–332. doi: 10.1016/S0140-6736(12)61140-4
   PubMed Web of Science ®Google Scholar
• Izumi K, Bieber K, Ludwig RJ. Current clinical trials in pemphigus and pemphigoid. Front Immunol. 2019;10:978. doi:10.3389/fimmu.2019.00978
   PubMed Web of Science ®Google Scholar
• Bertram F, Bröcker E-B, Zillikens D, et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7(5):434–439. doi: 10.1111/j.1610-0387.2008.06976.x
   PubMed Web of Science ®Google Scholar
• van Beek N, Weidinger A, Schneider SW, et al. Incidence of pemphigoid diseases in Northern Germany in 2016 – first data from the schleswig-holstein registry of autoimmune bullous diseases. J Eur Acad Dermatol Venereol. 2021;35(5):1197–1202. doi: 10.1111/jdv.17107
   PubMed Web of Science ®Google Scholar
• Schwarm C, Gola D, Holtsche MM, et al. Identification of two novel bullous pemphigoid- associated alleles, HLA-DQA1*05: 05 and -DRB1*07: 01, in Germans. Orphanet J Rare Dis. 2021;16(1):228. doi: 10.1186/s13023-021-01863-9
   PubMed Web of Science ®Google Scholar
• Kridin K, Hübner F, Recke A, et al. The burden of neurological comorbidities in six autoimmune bullous diseases: a population-based study. J Eur Acad Dermatol Venereol. 2021;35(10):2074–2078. doi: 10.1111/jdv.17465
   PubMed Web of Science ®Google Scholar
• Cortés B, Khelifa E, Clivaz L, et al. Mortality rate in bullous pemphigoid: a retrospective monocentric cohort study. Dermatology. 2012;225(4):320–325. doi: 10.1159/000345625
   PubMed Web of Science ®Google Scholar
• Ständer S, Hammers CM, Vorobyev A, et al. The impact of lesional inflammatory cellular infiltrate on the phenotype of bullous pemphigoid. J Eur Acad Dermatol Venereol. 2021;35(8):1702–1711. doi: 10.1111/jdv.17303
   PubMed Web of Science ®Google Scholar
• van Beek N, Knuth-Rehr D, Altmeyer P, et al. Diagnostics of autoimmune bullous diseases in German dermatology departments. J Dtsch Dermatol Ges. 2012;10(7):492–499. doi: 10.1111/j.1610-0387.2011.07840.x
   PubMed Web of Science ®Google Scholar
• Holtsche MM, Goletz S, van Beek N, et al. Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score. Br J Dermatol. 2018;179(4):918–924. doi: 10.1111/bjd.16553
   PubMed Web of Science ®Google Scholar
• van Beek N, Zillikens D, Schmidt E Bullous Autoimmune Dermatoses. Deutsches Ärzteblatt international [Internet]. 2021 [cited 2023 May 10]. Available from: https://www.aerzteblatt.de/610.3238/arztebl.m2021.0136
   Google Scholar
• Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370–379. doi: 10.1001/archderm.138.3.370
   PubMedGoogle Scholar
• Du G, Patzelt S, van Beek N, et al. Mucous membrane pemphigoid. Autoimmun Rev. 2022;21(4):103036. doi: 10.1016/j.autrev.2022.103036
   PubMed Web of Science ®Google Scholar
• Domloge-Hultsch N, Gammon WR, Briggaman RA, et al. Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. J Clin Invest. 1992;90(4):1628–1633. doi: 10.1172/JCI116033
   PubMed Web of Science ®Google Scholar
• Tyagi S, Bhol K, Natarajan K, et al. Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc Natl Acad Sci U S A. 1996;93(25):14714–14719. doi: 10.1073/pnas.93.25.14714
   PubMed Web of Science ®Google Scholar
• Schmidt E, Skrobek C, Kromminga A, et al. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol. 2001;145(5):778–783. doi: 10.1046/j.1365-2133.2001.04471.x
   PubMed Web of Science ®Google Scholar
• Cozzani E, Di Zenzo G, Calabresi V, et al. Autoantibody Profile of a Cohort of 78 Italian patients with mucous membrane pemphigoid: correlation between reactivity profile and clinical involvement. Acta Derm Venereol. 2016;96(6):768–773. doi: 10.2340/00015555-2311
   PubMed Web of Science ®Google Scholar
• Rashid H, Lamberts A, Borradori L, et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I. J Eur Acad Dermatol Venereol. 2021;35(9):1750–1764. doi: 10.1111/jdv.17397
   PubMed Web of Science ®Google Scholar
• Schmidt E, Rashid H, Marzano AV, et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II. J Eur Acad Dermatol Venereol. 2021;35(10):1926–1948. doi: 10.1111/jdv.17395
   PubMed Web of Science ®Google Scholar
• Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet. 2001;357(9271):1850–1851. doi: 10.1016/S0140-6736(00)04971-0
   PubMed Web of Science ®Google Scholar
• Goletz S, Probst C, Komorowski L, et al. A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid. Br J Dermatol. 2019;180(1):149–156. doi: 10.1111/bjd.17202
   PubMed Web of Science ®Google Scholar
• van Beek N, Kridin K, Bühler E, et al. Evaluation of site- and autoantigen-specific characteristics of mucous membrane pemphigoid. JAMA Dermatol. 2022;158(1):84–89. doi: 10.1001/jamadermatol.2021.4773
   PubMed Web of Science ®Google Scholar
• Kridin K, Schmidt E. Epidemiology of Pemphigus. JID Innov. 2021;1(1):100004. doi: 10.1016/j.xjidi.2021.100004
   PubMedGoogle Scholar
• Antiga E, Bech R, Maglie R, et al. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV). Acad Dermatol Venereol. 2023;37(6):1118–1134. doi: 10.1111/jdv.18931
   PubMed Web of Science ®Google Scholar
• Zimmermann J, Bahmer F, Rose C, et al. Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges. 2010;8(8):598–605. doi: 10.1111/j.1610-0387.2010.07380.x
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Amagai M, Watanabe K, et al. Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Invest Dermatol. 1995;104(5):829–834. doi: 10.1111/1523-1747.ep12607012
   PubMed Web of Science ®Google Scholar
• Probst C, Schlumberger W, Stöcker W, et al. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta. 2009;410(1–2):13–18. doi: 10.1016/j.cca.2009.08.022
   PubMed Web of Science ®Google Scholar
• Schepens I, Jaunin F, Begre N, et al. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. Plos One. 2010;5(8):e12250. doi: 10.1371/journal.pone.0012250
   PubMed Web of Science ®Google Scholar
• Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900–1913. doi: 10.1111/jdv.16752
   PubMed Web of Science ®Google Scholar
• Hofmann SC, Günther C, Böckle BC, et al. S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid. J Dtsch Dermatol Ges. 2022;20(11):1530–1550. doi: 10.1111/ddg.14905
   Web of Science ®Google Scholar
• Schmidt E, Sticherling M, Sárdy M, et al. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update. J Dtsch Dermatol Ges. 2020;18(5):516–526. doi: 10.1111/ddg.14097
   Web of Science ®Google Scholar
• Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36(10):1689–1704. doi: 10.1111/jdv.18220
   PubMed Web of Science ®Google Scholar
• Williams HC, Wojnarowska F, Kirtschig G, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017;389(10079):1630–1638. doi: 10.1016/S0140-6736(17)30560-3
   PubMed Web of Science ®Google Scholar
• Sticherling M, Franke A, Aberer E, et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol. 2017;177(5):1299–1305. doi: 10.1111/bjd.15649
   PubMed Web of Science ®Google Scholar
• Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol. 2002;138(7):903–908. doi: 10.1001/archderm.138.7.903
   PubMedGoogle Scholar
• Fichel F, Barbe C, Joly P, et al. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study. JAMA Dermatol. 2014;150(1):25–33. doi: 10.1001/jamadermatol.2013.5757
   PubMed Web of Science ®Google Scholar
• Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996;132(2):203–212. doi: 10.1001/archderm.1996.03890260105016
   PubMedGoogle Scholar
• Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–2040. doi: 10.1016/S0140-6736(17)30070-3
   PubMed Web of Science ®Google Scholar
• Pyzik M, Kozicky LK, Gandhi AK, et al. The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol. 2023;23(7):415–432. doi: 10.1038/s41577-022-00821-1
   PubMed Web of Science ®Google Scholar
• Zakrzewicz A, Würth C, Beckert B, et al. Stabilization of keratinocyte monolayer integrity in the presence of anti-desmoglein-3 antibodies through FcRn blockade with efgartigimod: novel treatment paradigm for pemphigus? Cells. 2022;11(6):942. doi: 10.3390/cells11060942
   PubMed Web of Science ®Google Scholar
• Maho-Vaillant M, Sips M, Golinski M-L, et al. FcRn antagonism leads to a decrease of desmoglein-specific B cells: secondary analysis of a phase 2 study of efgartigimod in pemphigus vulgaris and pemphigus foliaceus. Front Immunol. 2022;13:863095. DOI:10.3389/fimmu.2022.863095
   PubMed Web of Science ®Google Scholar
• Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13(3):176–189. doi: 10.1038/nri3401
   PubMed Web of Science ®Google Scholar
• Goebeler M, Bata-Csörgő Z, De Simone C, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol. 2022;186(3):429–439. doi: 10.1111/bjd.20782
   PubMed Web of Science ®Google Scholar
• Werth VP, Culton DA, Concha JSS, et al. Safety, tolerability, and activity of ALXN1830 targeting the neonatal fc receptor in chronic pemphigus. J Invest Dermatol. 2021;141(12):2858–2865.e4. doi: 10.1016/j.jid.2021.04.031
   PubMed Web of Science ®Google Scholar
• Sezin T, Murthy S, Attah C, et al. Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. JCI Insight. 2019;4(15):e128239, 128239. doi: 10.1172/jci.insight.128239
   PubMed Web of Science ®Google Scholar
• Sadik CD, Kim ND, Iwakura Y, et al. Neutrophils orchestrate their own recruitment in murine arthritis through C5aR and FcγR signaling. Proc Natl Acad Sci U S A. 2012;109(46):E3177–3185. doi: 10.1073/pnas.1213797109
   PubMed Web of Science ®Google Scholar
• Sadik CD, Rashid H, Hammers CM, et al. Evaluation of nomacopan for treatment of bullous pemphigoid: a phase 2a nonrandomized controlled trial. JAMA Dermatol. 2022;158(6):641. doi: 10.1001/jamadermatol.2022.1156
   PubMed Web of Science ®Google Scholar
• Cao P, Xu W, Rituximab ZL. Omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol. 2022;13:928621. doi:10.3389/fimmu.2022.928621
   PubMed Web of Science ®Google Scholar
• Moghadam P, Tancrede E, Bouaziz J-D, et al. Efficacity and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients. Br J Dermatol. 2023;189(2):244–246. doi: 10.1093/bjd/ljad136
   PubMed Web of Science ®Google Scholar
• Olbrich H, Sadik CD, Ludwig RJ, et al. Dupilumab in inflammatory skin diseases: a systematic review. Biomolecules. 2023;13(4):634. doi: 10.3390/biom13040634
   PubMed Web of Science ®Google Scholar
• Simon D, Yousefi S, Cazzaniga S, et al. Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study. 2020 [cited 2023 Apr 3]. Available from: https://boris.unibe.ch/132368/
   Google Scholar
• van Beek N, Lüttmann N, Huebner F, et al. Correlation Of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol. 2017;153(1):30. doi: 10.1001/jamadermatol.2016.3357
   PubMed Web of Science ®Google Scholar
• De D, Kaushik A, Handa S, et al. Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co‐morbidities. Acad Dermatol Venereol [Internet]. 35 2021 [cited 2023 Apr 4]. Available from: https://onlinelibrary.wiley.com/doi/10.1111/jdv.17229
   Google Scholar
• Konstantinou MP, Jendoubi F, Fortenfant F, et al. Successful treatment of recalcitrant pemphigoid gestationis with omalizumab: report of two cases. Acad Dermatol Venereol [Internet]. 2022 [cited 2023 Apr 5];36(9):e720–e722. Available from: https://onlinelibrary.wiley.com/doi/10.1111/jdv.18227
   PubMed Web of Science ®Google Scholar
• Chakievska L, Holtsche MM, Künstner A, et al. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun. 2019;96:104–112. DOI:10.1016/j.jaut.2018.09.003
   PubMed Web of Science ®Google Scholar
• Ge X, Li S, Jin X, et al. Treatment of bullous pemphigoid in Chinese patients with Tripterygium wilfordii Hook F. Dermatologic Therapy [Internet]. 33 2020 [cited 2023 Apr 4];33(4):e13721. Available from: https://onlinelibrary.wiley.com/doi/10.1111/dth.13721
   PubMed Web of Science ®Google Scholar
• Darouti MAE, Khattab MAF, Hegazy RA, et al. Pentoxifylline (Anti-Tumor Necrosis Factor Drug): Effective Adjuvant Therapy in the Control of Ocular Cicatricial Pemphigoid. Eur J Ophthalmol. 2011;21(5):529–537. doi: 10.5301/EJO.2011.6294
   PubMed Web of Science ®Google Scholar
• Timoteo RP, da Silva MV, Miguel CB, et al. Th1/th17-Related Cytokines and Chemokines and Their Implications in the Pathogenesis of Pemphigus Vulgaris. Mediators Inflamm. 2017;2017:1–9. DOI:10.1155/2017/7151285
   Web of Science ®Google Scholar
• Hall RP, Fairley J, Woodley D, et al. A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol. 2015;172(3):760–768. doi: 10.1111/bjd.13350
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Garcia MS, Rehmus W, et al. A Pilot Study of Etanercept Treatment for Pemphigus Vulgaris. Arch Dermatol. 2010;147(1):117. doi: 10.1001/archdermatol.2010.409
   Google Scholar
• Murrell DF, Patsatsi A, Stavropoulos P, et al. Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*. Br J Dermatol. 2021;185(4):745–755. doi: 10.1111/bjd.20431
   PubMed Web of Science ®Google Scholar
• Murrell DF, Patsatsi A, Stavropoulos P, et al. Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris. Acad Dermatol Venereol [Internet]. 36 2022 [cited 2023 Apr 4]. Available from: doi: 10.1111/jdv.18318
   Google Scholar
• James H, Paley GL, Brasington R, et al. Tofacitinib for refractory ocular mucous membrane pemphigoid. Am J Ophthalmol Case Rep. 2021;22:101104. doi: 10.1016/j.ajoc.2021.101104
   PubMedGoogle Scholar
• Burningham KM, Cao J, Dominguez AR. Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate. JAAD Case Rep. 2022;27:67–69. doi:10.1016/j.jdcr.2022.07.013
   PubMedGoogle Scholar
• Ellebrecht CT, Bhoj VG, Nace A, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353(6295):179–184. doi: 10.1126/science.aaf6756
   PubMed Web of Science ®Google Scholar
• Schmidt E, Klinker E, Opitz A, et al. Protein a immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol. 2003;148(6):1222–1229. doi: 10.1046/j.1365-2133.2003.05302.x
   PubMed Web of Science ®Google Scholar
• Shimanovich I, Herzog S, Schmidt E, et al. Improved protocol for treatment of pemphigus vulgaris with protein a immunoadsorption. Clin Exp Dermatol. 2006;31(6):768–774. doi: 10.1111/j.1365-2230.2006.02220.x
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, Shimanovich I, Meier M, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol. 2012;166(1):154–160. doi: 10.1111/j.1365-2133.2011.10585.x
   PubMed Web of Science ®Google Scholar
• Van Beek N, Eming R, Reuß A, et al. FV04/06 Wirksamkeit und Sicherheit der adjuvanten Immunadsorption bei Pemphigus vulgaris und Pemphigus foliaceus (IA-Pem-Studie): eine multizentrische randomisierte kontrollierte Studie. J Deutsche Derma Gesell. 2023;21:9–27.
   PubMedGoogle Scholar
• Holtsche MM, Van Beek N, Kasperkiewicz M, et al. FV02/02 Adjuvante Therapie des schweren und/oder refraktären bullösen Pemphigoid mit Immunadsorption - Eine prospektive monozentrische explorative Pilotstudie. J Deutsche Derma Gesell. 2023;21:9–27.
   PubMedGoogle Scholar
• Rahmatpour Rokni G, Shiran M, Abounoori M, et al. Effects of metformin on autoimmune immunoglobins and interferon‐γ in patients with early diagnosed pemphigus vulgaris: a prospective clinical trial. Clin Experimental Derm. 2022;47(1):110–113. doi: 10.1111/ced.14832
   PubMed Web of Science ®Google Scholar
• Schilf P, Schmitz M, Derenda-Hell A, et al. Inhibition of Glucose Metabolism Abrogates the Effector Phase of Bullous Pemphigoid-Like Epidermolysis Bullosa Acquisita. J Invest Dermatol. 2021;141(7):1646–1655.e3. doi: 10.1016/j.jid.2021.01.014
   PubMed Web of Science ®Google Scholar
• Iraji F, Faghihi G, Siadat AH. The efficacy of acyclovir in treatment of the pemphigus vulgaris. J Res Med Sci. 2013;18(11):976–978.
   PubMed Web of Science ®Google Scholar
• Liu B, Li Z, Du M. Effects of jingui shenqi pill combined prednisone on expression of glucocorticoid receptor and its clinical effect in treating bullous pemphigoid patients. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006;26(10):881–884.
   PubMedGoogle Scholar
• Kuter DJ, Efraim M, Mayer J, et al. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022;386(15):1421–1431. doi: 10.1056/NEJMoa2110297
   PubMed Web of Science ®Google Scholar
• Li N, Zhao M, Hilario-Vargas J, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest. 2005;115(12):3440–3450. doi: 10.1172/JCI24394
   PubMed Web of Science ®Google Scholar